according to the OSHA Hazard Communication Standard



# **Rizatriptan Orally Disintegrating Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
7.0	04/06/2024	809075-00016	Date of first issue: 07/22/2016

#### **SECTION 1. IDENTIFICATION**

Product name		Rizatriptan Orally Disintegrating Formulation				
Manufacturer or supplier's o	Manufacturer or supplier's details					
Company name of supplier	:	Organon & Co.				
Address	:	30 Hudson Street, 33nd floor				
		Jersey City, New Jersey, U.S.A 07302				
Telephone	:	1-551-430-6000				
Emergency telephone	:	1-215-631-6999				
E-mail address	:	EHSSTEWARD@organon.com				
Recommended use of the chemical and restrictions on use						
Recommended use	:	Pharmaceutical				

: Not applicable

#### **SECTION 2. HAZARDS IDENTIFICATION**

Restrictions on use

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR
1910.1200)
Combustible dust

Skin sensitization	:	Category 1
Reproductive toxicity	:	Category 2
Specific target organ toxicity - repeated exposure (Oral)	:	Category 1 (Cardio-vascular system)

### **GHS** label elements

Hazard pictograms	:	
Signal Word	:	Danger
Hazard Statements	:	If small particles are generated during further processing, han- dling or by other means, may form combustible dust concentra- tions in air. H317 May cause an allergic skin reaction. H361d Suspected of damaging the unborn child. H372 Causes damage to organs (Cardio-vascular system) through prolonged or repeated exposure if swallowed.
Precautionary Statements	:	Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust.

according to the OSHA Hazard Communication Standard



## **Rizatriptan Orally Disintegrating Formulation**

Version 7.0	Revision Date: 04/06/2024	SDS Number: 809075-00016	Date of last issue: 09/30/2023 Date of first issue: 07/22/2016	
		P270 Do not ea P272 Contamir the workplace.	in thoroughly after handling. at, drink or smoke when using this product. hated work clothing must not be allowed out of htective gloves, protective clothing, eye protection ction.	
		Response: P302 + P352 IF ON SKIN: Wash with plenty of soap and water. P308 + P313 IF exposed or concerned: Get medical attention. P333 + P313 If skin irritation or rash occurs: Get medical atten- tion. P363 Wash contaminated clothing before reuse. Storage: P405 Store locked up.		
		<b>Disposal:</b> P501 Dispose disposal plant.	of contents and container to an approved waste	

#### Other hazards

Dust contact with the eyes can lead to mechanical irritation.

#### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture	: Mixture	
Components		
Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 10 - < 20
Aspartame	22839-47-0	>= 5 - < 10
Peppermint oil	8006-90-4	>= 1 - < 5
Starch	9005-25-8	>= 1 - < 5
Rizatriptan	145202-66-0	>= 1 - < 5
Actual concentration is withh	eld as a trade secret	

Actual concentration is withheld as a trade secret

### **SECTION 4. FIRST AID MEASURES**

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting.



## **Rizatriptan Orally Disintegrating Formulation**

Version 7.0	Revision Date: 04/06/2024	SDS Number: 809075-00016	Date of last issue: 09/30/2023 Date of first issue: 07/22/2016		
	mportant symptoms ffects, both acute and ed	<ul> <li>Get medical attention.</li> <li>Rinse mouth thoroughly with water.</li> <li>May cause an allergic skin reaction.</li> <li>Suspected of damaging the unborn child.</li> <li>Causes damage to organs through prolonged or repeated exposure if swallowed.</li> </ul>			
Protection of first-aiders Notes to physician		Dust contact w First Aid respon and use the red when the poter	Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). Treat symptomatically and supportively.		

#### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides Nitrogen oxides (NOx)
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

#### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).

according to the OSHA Hazard Communication Standard



## **Rizatriptan Orally Disintegrating Formulation**

Version 7.0	Revision Date: 04/06/2024	SDS Number: 809075-00016	Date of last issue: 09/30/2023 Date of first issue: 07/22/2016
		surfaces, as th released into the Local or nation disposal of this employed in the determine which Sections 13 ar	should not be allowed to accumulate on hese may form an explosive mixture if they are he atmosphere in sufficient concentration. hal regulations may apply to releases and s material, as well as those materials and items he cleanup of releases. You will need to ch regulations are applicable. hd 15 of this SDS provide information regarding r national requirements.
SECTION	7. HANDLING AND S	TORAGE	
Tech	nical measures	causing an exp Provide adequ	ry may accumulate and ignite suspended dust blosion. ate precautions, such as electrical grounding or inert atmospheres.
	l/Total ventilation ce on safe handling	: Use only with a Do not get on a Do not breathe Do not swallow Avoid contact Wash skin tho Handle in acco practice, base assessment	adequate ventilation. skin or clothing. e dust. v.

		Minimize dust generation and accumulation.
		Keep container closed when not in use.
		Keep away from heat and sources of ignition.
		Take precautionary measures against static discharges.
		Do not eat, drink or smoke when using this product.
		Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage	:	Keep in properly labeled containers.
-		Store in accordance with the particular national regulations.
Materials to avoid	:	Do not store with the following product types:
		Strong oxidizing agents
		Self-reactive substances and mixtures
		Organic peroxides
		Explosives
		Gases

#### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

inert or nuisance dust	50 Million particles per cubic foot Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	15 mg/m³ Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3

according to the OSHA Hazard Communication Standard



### **Rizatriptan Orally Disintegrating Formulation**

ersion D	Revision Date: 04/06/2024	SDS Number: 809075-00016		t issue: 09/30/2023 t issue: 07/22/2016	
		5 mg/m³ Value type (Fo Basis: OSHA 2		: TWA (respirable fra	ction)
				oot : TWA (respirable fra	ction)
Dust, ticulat	nuisance dust and par- tes	10 mg/m³ Value type (Fo Basis: CAL PE		: PEL (Total dust)	
		5 mg/m³ Value type (Fo Basis: CAL PE		: PEL (respirable dus	t fraction)
Comp	ponents	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Cellul	ose	9004-34-6	TŴA	10 mg/m <sup>3</sup>	ACGIH
			TWA (Res- pirable)	5 mg/m <sup>3</sup>	NIOSH REL
			TWA (total)	10 mg/m <sup>3</sup>	NIOSH REL
			TWA (total dust)	15 mg/m <sup>3</sup>	OSHA Z-1
			TWA (respir- able fraction)	5 mg/m³	OSHA Z-1
Peppe	ermint oil	8006-90-4	TWA (mist - total)	10 mg/m <sup>3</sup>	NIOSH REL
			TWA (mist - respirable)	5 mg/m <sup>3</sup>	NIOSH REL
Starc	h	9005-25-8	TWA	10 mg/m <sup>3</sup>	ACGIH
			TWA (Res- pirable)	5 mg/m³	NIOSH REL
			TWA (total)	10 mg/m <sup>3</sup>	NIOSH REL
			TWA (total dust)	15 mg/m³	OSHA Z-1
			TWA (respir- able fraction)	5 mg/m³	OSHA Z-1
Rizatr	riptan	145202-66-0	TWA	10 µg/m3 (OEB 3)	Internal
			Wipe limit	100 µg/100 cm <sup>2</sup>	Internal

**Engineering measures** 

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

#### Personal protective equipment

:

according to the OSHA Hazard Communication Standard



## **Rizatriptan Orally Disintegrating Formulation**

Version 7.0	Revision Date: 04/06/2024	SDS Number: 809075-00016	Date of last issue: 09/30/2023 Date of first issue: 07/22/2016
	iratory protection	maintain vapor concentrations unknown, app Follow OSHA use NIOSH/M by air purifying hazardous che supplied respin release, expos	ocal exhaust ventilation is recommended to r exposures below recommended limits. Where a are above recommended limits or are ropriate respiratory protection should be worn. respirator regulations (29 CFR 1910.134) and SHA approved respirators. Protection provided g respirators against exposure to any emical is limited. Use a positive pressure air rator if there is any potential for uncontrolled sure levels are unknown, or any other where air purifying respirators may not provide ection.
	aterial	: Chemical-resis	stant gloves
	emarks protection	If the work env mists or aeros Wear a facesh	ble gloving. lasses with side shields or goggles. vironment or activity involves dusty conditions, ols, wear the appropriate goggles. ield or other full face protection if there is a rect contact to the face with dusts, mists, or
Skin a	and body protection	: Work uniform of Additional bod task being per disposable sui	or laboratory coat. y garments should be used based upon the formed (e.g., sleevelets, apron, gauntlets, ts) to avoid exposed skin surfaces. te degowning techniques to remove potentially clothing.
Hygie	ene measures	: If exposure to eye flushing sy working place. When using do Contaminated workplace. Wash contami The effective of engineering co appropriate de industrial hygie	chemical is likely during typical use, provide stems and safety showers close to the

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
рН	:	No data available

according to the OSHA Hazard Communication Standard



## **Rizatriptan Orally Disintegrating Formulation**

Vers 7.0	sion	Revision Date: 04/06/2024		S Number: 075-00016	Date of last issue: 09/30/2023 Date of first issue: 07/22/2016
	Melting	point/freezing point	:	No data available	
	Initial bo range	biling point and boiling	:	No data available	
	Flash p	oint	:	Not applicable	
	Evapora	ation rate	:	No data available	
	Flamma	ability (solid, gas)	:	May form explosition handling or other	ve dust-air mixture during processing, means.
	Flamma	ability (liquids)	:	No data available	
		explosion limit / Upper bility limit	:	No data available	
		explosion limit / Lower bility limit	:	No data available	
	Vapor p	ressure	:	No data available	
	Relative	e vapor density	:	No data available	
	Relative	e density	:	No data available	
	Density		:	No data available	
	Solubilit Wate	y(ies) er solubility	:	No data available	
	Partitior octanol/	n coefficient: n-	:	No data available	
		ition temperature	:	No data available	
	Decomp	position temperature	:	No data available	
	Viscosit Visc	y osity, kinematic	:	No data available	
	Explosiv	ve properties	:	Not explosive	
	Oxidizir	g properties	:	The substance or	mixture is not classified as oxidizing.
	Molecul	ar weight	:	No data available	
	Particle Particle	characteristics size	:	No data available	

### SECTION 10. STABILITY AND REACTIVITY



## **Rizatriptan Orally Disintegrating Formulation**

Version 7.0	Revision Date: 04/06/2024		S Number: 9075-00016	Date of last issue: 09/30/2023 Date of first issue: 07/22/2016
Ch	activity emical stability ssibility of hazardous reac- is	:	Stable under nor May form explos handling or other	ive dust-air mixture during processing,
Inc Ha:	nditions to avoid ompatible materials zardous decomposition ducts	:	Heat, flames and Avoid dust forma Oxidizing agents No hazardous de	tion.

#### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

internation on intery road		shpoodi c
Inhalation Skin contact Ingestion Eye contact		
Acute toxicity		
Not classified based on ava	ailable	information.
Product:		
Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
Components:		
Cellulose:		
Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg
Aspartame:		

		Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg
Aspartame:		
Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Peppermint oil:		
Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg
Acute dermal toxicity	:	LD50 (Rabbit): > 5,000 mg/kg
Starch:		
Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

according to the OSHA Hazard Communication Standard



ersion .0	Revision Date: 04/06/2024	SDS Number: 809075-00016	Date of last issue: 09/30/2023 Date of first issue: 07/22/2016
Rizat	riptan:		
Acute	oral toxicity	: LD50 (Rat): 2,2	227 mg/kg
		LD50 (Mouse):	: 700 - 1,631 mg/kg
-	corrosion/irritation lassified based on ava	ilable information.	
<u>Com</u>	oonents:		
Рерр	ermint oil:		
Speci		: Rabbit	
Resul Rema		: Skin irritation	from similar materials
IVenie		. Dased on data	
Rizat	riptan:		
Speci		: Rabbit	
Resu	lt	: No skin irritatio	n
-	lt		es, reversing within 21 days from similar materials
Starc	h:		
Speci		: Rabbit	
Resu	lt	: No eye irritatio	n
Rizat	riptan:		
Speci	•	: Bovine cornea	
Rema		: Moderate eye i	irritation
Resp	iratory or skin sensi	tization	
-	sensitization		
	cause an allergic skin		
•	iratory sensitization lassified based on ava	ilable information.	
<u>Com</u>	oonents:		
Рерр	ermint oil:		
Test Route Speci	es of exposure	: Local lymph no : Skin contact : Mouse	ode assay (LLNA)

according to the OSHA Hazard Communication Standard



/ersion '.0	Revision Date: 04/06/2024	SDS Number: 809075-00016	Date of last issue: 09/30/2023 Date of first issue: 07/22/2016
Metho Resul Rema	lt	: OECD Test C : positive : Based on dat	Guideline 429 a from similar materials
Asses	ssment	: Probability or	evidence of skin sensitization in humans
Starc Test ⊺ Route Speci Resul	Гуре es of exposure es	: Maximization : Skin contact : Guinea pig : negative	Test
Test Route Speci	es of exposure es ssment	: Maximization : Dermal : Guinea pig : Does not cau : negative	Test se skin sensitization.
Not cl	a <b>cell mutagenicity</b> lassified based on ava conents:	ailable information.	
Cellu			
	toxicity in vitro	: Test Type: B Result: negat	acterial reverse mutation assay (AMES) ive
		Test Type: In Result: negat	vitro mammalian cell gene mutation test ive
Geno	toxicity in vivo	cytogenetic a Species: Mou	use oute: Ingestion
II Aspa	rtame:		
	toxicity in vitro	: Test Type: B Result: nega	acterial reverse mutation assay (AMES) ive
			NA damage and repair, unscheduled DNA syn- nmalian cells (in vitro) ive
Geno	toxicity in vivo	cytogenetic to Species: Rat	utagenicity (in vivo mammalian bone-marrow est, chromosomal analysis) oute: Ingestion ive

according to the OSHA Hazard Communication Standard



0	Revision Date: 04/06/2024	SDS Number: 809075-00016	Date of last issue: 09/30/2023 Date of first issue: 07/22/2016
Starc	h:		
Geno	toxicity in vitro	: Test Type: Bad Result: negativ	cterial reverse mutation assay (AMES) /e
Rizat	riptan:		
Geno	toxicity in vitro	: Test Type: Bad Result: negativ	cterial reverse mutation assay (AMES) /e
		Test Type: Alk Result: negativ	aline elution assay /e
		Test Type: In v Result: negativ	vitro mammalian cell gene mutation test
		Test Type: Chi Result: negativ	romosome aberration test in vitro /e
Geno	toxicity in vivo	: Test Type: Ma cytogenetic as Species: Mous Application Ro Result: negativ	e ute: Oral
Not c	nogenicity lassified based on av ponents:	ailable information.	
<b>Cellulose:</b> Species Application Route			
Applic	es cation Route	: Rat : Ingestion : 72 weeks	
Applic	es cation Route sure time	: Ingestion	
Applic Expos Resu	es cation Route sure time It	: Ingestion : 72 weeks	
Applio Expos Resul	es cation Route sure time It <b>rtame:</b> es	: Ingestion : 72 weeks	
Applic Expos Resul Aspa Speci Applic	es cation Route sure time It <b>rtame:</b> es cation Route	: Ingestion : 72 weeks : negative : Rat : Ingestion	
Applic Expos Resul Aspa Speci Applic	es cation Route sure time It <b>rtame:</b> es cation Route sure time	: Ingestion : 72 weeks : negative : Rat	
Applid Expos Result Aspa Speci Applid Expos Result	es cation Route sure time It <b>rtame:</b> es cation Route sure time It	<ul> <li>Ingestion</li> <li>72 weeks</li> <li>negative</li> <li>Rat</li> <li>Ingestion</li> <li>104 weeks</li> </ul>	
Applid Expos Resul Aspa Speci Applid Expos Resul Rizat	es cation Route sure time It <b>rtame:</b> es cation Route sure time It <b>riptan:</b>	<ul> <li>Ingestion</li> <li>72 weeks</li> <li>negative</li> <li>Rat</li> <li>Ingestion</li> <li>104 weeks</li> <li>negative</li> </ul>	
Applid Expos Result Aspa Speci Applid Expos Result Rizat Speci Applid	es cation Route sure time It <b>rtame:</b> es cation Route sure time It <b>riptan:</b> es cation Route	<ul> <li>Ingestion</li> <li>72 weeks</li> <li>negative</li> <li>Rat</li> <li>Ingestion</li> <li>104 weeks</li> <li>negative</li> <li>Mouse</li> <li>Oral</li> </ul>	
Applid Expos Resul Aspa Speci Applid Expos Resul Speci Applid Expos	es cation Route sure time It <b>rtame:</b> es cation Route sure time It <b>riptan:</b> es cation Route sure time	<ul> <li>Ingestion</li> <li>72 weeks</li> <li>negative</li> <li>Rat</li> <li>Ingestion</li> <li>104 weeks</li> <li>negative</li> </ul> Mouse <ul> <li>Oral</li> <li>100 weeks</li> </ul>	hu u ciabt
Applid Expos Result Aspa Speci Applid Expos Result Rizat Speci Applid	es cation Route sure time It <b>rtame:</b> es cation Route sure time It <b>riptan:</b> es cation Route sure time EL	<ul> <li>Ingestion</li> <li>72 weeks</li> <li>negative</li> <li>Rat</li> <li>Ingestion</li> <li>104 weeks</li> <li>negative</li> <li>Mouse</li> <li>Oral</li> </ul>	ły weight
Applid Expos Result Aspa Speci Applid Expos Result Speci Applid Expos NOAE	es cation Route sure time It <b>rtame:</b> es cation Route sure time It <b>riptan:</b> les cation Route sure time EL	<ul> <li>Ingestion</li> <li>72 weeks</li> <li>negative</li> <li>Rat</li> <li>Ingestion</li> <li>104 weeks</li> <li>negative</li> <li>Mouse</li> <li>Oral</li> <li>100 weeks</li> <li>125 mg/kg book</li> </ul>	ly weight
Applid Expos Result Aspa Speci Applid Expos Result Speci Applid Expos NOAE Result	es cation Route sure time It <b>rtame:</b> es cation Route sure time It <b>riptan:</b> es cation Route sure time EL t t	<ul> <li>Ingestion</li> <li>72 weeks</li> <li>negative</li> <li>Rat</li> <li>Ingestion</li> <li>104 weeks</li> <li>negative</li> <li>Mouse</li> <li>Oral</li> <li>100 weeks</li> <li>125 mg/kg boo</li> <li>negative</li> <li>Rat</li> <li>Oral</li> <li>Oral</li> </ul>	ły weight
Applid Expos Result Aspa Speci Applid Expos Result Speci Applid Expos NOAE Result	es cation Route sure time It rtame: es cation Route sure time It riptan: es cation Route sure time EL It es cation Route sure time	<ul> <li>Ingestion</li> <li>72 weeks</li> <li>negative</li> <li>Rat</li> <li>Ingestion</li> <li>104 weeks</li> <li>negative</li> <li>Mouse</li> <li>Oral</li> <li>100 weeks</li> <li>125 mg/kg boo</li> <li>negative</li> <li>Rat</li> </ul>	

according to the OSHA Hazard Communication Standard



Version 7.0	Revision Date: 04/06/2024	SDS Number: 809075-00016	Date of last issue: 09/30/2023 Date of first issue: 07/22/2016		
Result		: negative			
IARC	Group 2B: Pc Aspartame	ossibly carcinogeni	c to humans 22839-47-0		
II OSHA		nt of this product p st of regulated card	resent at levels greater than or equal to 0.1% is inogens.		
NTP		No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.			
Suspe	ductive toxicity cted of damaging the u	nborn child.			
<u>Comp</u>	onents:				
Cellul					
Effects	s on fertility	Species: Rat	ne-generation reproduction toxicity study oute: Ingestion ive		
Effects	s on fetal development	Species: Rat	ertility/early embryonic development oute: Ingestion ive		
Aspar	tame:				
	s on fertility	Species: Rat	vo-generation reproduction toxicity study oute: Ingestion ive		
Effects	s on fetal development	Species: Rat	nbryo-fetal development oute: Ingestion ive		
∎ Rizatr	iptan:				
	s on fertility	Species: Rat, Application R Fertility: LOA Symptoms: a Result: No ef			
		Species: Rat, Application R Fertility: NOA			
		10 /			

according to the OSHA Hazard Communication Standard



Versior 7.0	n Revision Date: 04/06/2024		0S Number: 9075-00016	Date of last issue: 09/30/2023 Date of first issue: 07/22/2016
I			development were	e detected.
Ef	fects on fetal development	:	Species: Rat Application Route Developmental To	o-fetal development : Oral oxicity: LOAEL: 10 mg/kg body weight genic effects., Embryo-fetal toxicity.
			Species: Rabbit Application Route Developmental To Result: No teratog	o-fetal development : Oral oxicity: LOAEL: 100 mg/kg body weight genic effects., Embryo-fetal toxicity. ects were seen only at maternally toxic dos-
	eproductive toxicity - As- essment	:	Some evidence or animal experiment	f adverse effects on development, based on ts.
	FOT-single exposure			
	ot classified based on availa	ble	information.	
	omponents:			
	zatriptan: ssessment	:	May cause drows	iness or dizziness.
Ca	<b>FOT-repeated exposure</b> auses damage to organs (Ca vallowed.	ardi	o-vascular system)	through prolonged or repeated exposure if
<u>Co</u>	omponents:			
Та	zatriptan: arget Organs ssessment	:	Cardio-vascular s Causes damage t exposure.	ystem o organs through prolonged or repeated
Re	epeated dose toxicity			
<u>C</u>	omponents:			
Ce	ellulose:			
	Decies DAEL	÷	Rat >= 9,000 mg/kg	
	oplication Route cosure time	:	Ingestion 90 Days	
As	spartame:			
Sp	pecies	:	Rat	
	OAEL oplication Route	:	>= 4,000 mg/kg Ingestion	
			12/20	

according to the OSHA Hazard Communication Standard



## **Rizatriptan Orally Disintegrating Formulation**

Version 7.0	Revision Date: 04/06/2024	SDS N 809075	umber: -00016	Date of last issue: 09/30/2023 Date of first issue: 07/22/2016
Expos	sure time	: 104	Weeks	
	es EL cation Route sure time	: Skii : 28	2,000 mg/kg n contact Days CD Test Guic	leline 410
Speci LOAE Applic	L cation Route sure time	: Ora : 14 \	g/kg I Weeks	pupil, Increased pulse rate, Redness
	L cation Route sure time	: Intra : 2 W	5 mg/kg avenous /eeks	pupil, Increased pulse rate, Redness
	L cation Route sure time	: Ora : 1 y	mg/kg	pupil
Not cl	ation toxicity assified based on ava rience with human ex		mation.	
	oonents: riptan: tion	Syr		Cardio-vascular system enia, Fatigue, Pain, Dizziness, Weakness,
	12. ECOLOGICAL IN exicity	FORMATI	ON	
Cellu	oonents: lose: ity to fish	Exp	osure time: 4	tipes (Japanese medaka)): > 100 mg/l l8 h lon data from similar materials

Remarks: Based on data from similar materials

#### Aspartame:

according to the OSHA Hazard Communication Standard



Version 7.0	Revision Date: 04/06/2024		9075-00016	Date of last issue: 09/30/2023 Date of first issue: 07/22/2016
Toxicity	Toxicity to fish		LC50 (Danio rerio (zebra fish)): > 20 g/l Exposure time: 96 h	
	y to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
Toxicity plants	y to algae/aquatic	:	ErC50 (Desmodes Exposure time: 72 Method: OECD Te	
Peppe	rmint oil:			
	y to fish	:	Exposure time: 96	(zebra fish)): > 10 - 100 mg/l i h on data from similar materials
	y to daphnia and other invertebrates	:	Exposure time: 48	agna (Water flea)): > 10 - 100 mg/l 5 h on data from similar materials
Toxicit <u>y</u> plants	y to algae/aquatic	:	mg/l Exposure time: 72	mus subspicatus (green algae)): > 10 - 100 ! h on data from similar materials
Toxicity	y to microorganisms	:	EC10: 51 mg/l Exposure time: 3 Remarks: Based o	n on data from similar materials
Rizatri	ptan:			
	y to fish	:	LC50 (Pimephales Exposure time: 96	s promelas (fathead minnow)): > 1,000 mg/l i h
	y to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48	agna (Water flea)): 1,000 mg/l s h
Toxicity plants	y to algae/aquatic	:	EC50 (Pseudokiro mg/l Exposure time: 72 Method: OECD Te	
			NOEC (Pseudokir mg/l Exposure time: 72 Method: OECD Te	
Toxicity icity)	y to fish (Chronic tox-	:	NOEC (Pimephale Exposure time: 32 Method: OECD Te	
	y to daphnia and other c invertebrates (Chron-	:	NOEC (Daphnia r Exposure time: 21	nagna (Water flea)): 110 mg/l d

according to the OSHA Hazard Communication Standard



Version 7.0	Revision Date: 04/06/2024		9075-00016	Date of last issue: 09/30/2023 Date of first issue: 07/22/2016		
ic toxic	city)		Method: OECD Test Guideline 211			
Toxicit	ty to microorganisms	:	EC50: > 1,000 mg Exposure time: 3 Test Type: Respir Method: OECD Te	h ration inhibition		
			NOEC: 1,000 mg/ Exposure time: 3 Test Type: Respir Method: OECD Te	h ration inhibition		
Persis	stence and degradabi	lity				
<u>Comp</u>	onents:					
Cellul	ose:					
Biode	gradability	:	Result: Readily bi	odegradable.		
Aspar	tame:					
Biodeç	gradability	:	Result: Readily bi Method: OECD To	odegradable. est Guideline 301F		
Рерре	ermint oil:					
Biodeç	gradability	:	,	odegradable. on data from similar materials		
Rizatr	iptan:					
	gradability	:	Result: Not readily Biodegradation: 5 Exposure time: 13 Method: OECD To	50 % 3 d		
II Bioac	cumulative potential					
<u>Comp</u>	onents:					
Aspar	tame:					
	on coefficient: n- bl/water	:	log Pow: 0.07 Remarks: Calcula	tion		
Рерре	ermint oil:					
	on coefficient: n- bl/water	:	log Pow: > 4 Remarks: Based o	on data from similar materials		
Rizatr	iptan:					
Partitio	on coefficient: n- bl/water	:	log Pow: -0.649			

according to the OSHA Hazard Communication Standard



## **Rizatriptan Orally Disintegrating Formulation**

Versio 7.0	n Revision Date: 04/06/2024	SDS Number: 809075-00016	Date of last issue: 09/30/2023 Date of first issue: 07/22/2016
Μ	obility in soil		
<u>C</u>	omponents:		
R	izatriptan:		
	istribution among environ- ental compartments	: log Koc: 3.83 Method: OECI	D Test Guideline 106
0	ther adverse effects		
N	o data available		
SECTI	ON 13. DISPOSAL CONSI	DERATIONS	
	isposal methods		
W	aste from residues		accordance with local regulations.
C	ontaminated packaging	: Empty contain handling site for	e of waste into sewer. ers should be taken to an approved waste or recycling or disposal. e specified: Dispose of as unused product.
SECTI	ON 14. TRANSPORT INFO	RMATION	
In	ternational Regulations		
-	NRTDG ot regulated as a dangerous	s good	
	TA-DGR ot regulated as a dangerous	s good	
IN	IDG-Code		

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### **Domestic regulation**

**49 CFR** Not regulated as a dangerous good

### Special precautions for user

Not applicable

#### SECTION 15. REGULATORY INFORMATION

#### **CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

#### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity** This material does not contain any components with a section 302 EHS TPQ.

according to the OSHA Hazard Communication Standard



## **Rizatriptan Orally Disintegrating Formulation**

ersion 0	Revision Date: 04/06/2024	SDS Number: 809075-00016	Date of last issue Date of first issue	
SAR	A 311/312 Hazards	Reproductiv	or skin sensitization	or repeated exposure)
SAR	A 313	known CAS		chemical components with the threshold (De Minimis) A Title III, Section 313.
US S	tate Regulations			
Penn	sylvania Right To Kr	ow		
	Gelatins D-mannitol Cellulose Glycine D-Glucose, 4-O-f Aspartame Peppermint oil Starch	3-D-galactopyranos	yl-, monohydrate	9000-70-8 69-65-8 9004-34-6 56-40-6 64044-51-5 22839-47-0 8006-90-4 9005-25-8
Califo	ornia Prop. 65			
				z, which is/are known to w.P65Warnings.ca.gov.
Califo	ornia Permissible Ex	posure Limits for	Chemical Contaminant	ts
	Cellulose Peppermint oil Starch			9004-34-6 8006-90-4 9005-25-8
The i	ngredients of this pro	oduct are reported	I in the following inver	ntories:
AICS		: not determin	ned	
DSL		: not determin	ned	


### **SECTION 16. OTHER INFORMATION**

**Further information** 

according to the OSHA Hazard Communication Standard



### **Rizatriptan Orally Disintegrating Formulation**



OSHA Z-3 / TWA : 8-hour time weighted average AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Haz-

German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Pre-



### Rizatriptan Orally Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
7.0	04/06/2024	809075-00016	Date of first issue: 07/22/2016

vention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

	1	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/
--	---	---	--

Revision Date : 04/06/2024

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8